Xtalks — The Life Science Community™, Online webinar
2026-12-01
Neuroscience clinical development is evolving across Alzheimer’s disease, Parkinson’s disease, psychiatry and other complex CNS disorders. Disease heterogeneity, trial accessibility, endpoint selection and variability in treatment response are challenging traditional approaches to how sponsors identify patients, measure treatment effects and make development decisions. This webinar will explore how sponsors are addressing these challenges across neuroscience. Panelists will examine approaches to patient identification and enrollment, why traditional measures of treatment response are being re-examined and how sponsors are evaluating endpoints that better capture clinically meaningful change. Examples from neurodegenerative disease, psychiatry and emerging fields such as psychedelic medicine will illustrate how patient populations, endpoints and measures of treatment response are influencing trial design and execution. The discussion will also look ahead at the scientific, operational and regulatory trends likely to shape neuroscience development over the next five years. Attendees will gain practical insights into how sponsors are adapting development strategies across CNS disorders, from identifying appropriate patient populations and selecting meaningful endpoints to navigating evolving trial requirements and applying study data to development decisions. Register for this webinar to learn how evolving approaches to neuroscience clinical development can inform patient identification, endpoint selection and future clinical trial strategies.
|